Genmab A/S (NASDAQ:GMAB) Receives “Underweight” Rating from Morgan Stanley

Genmab A/S (NASDAQ:GMAB)‘s stock had its “underweight” rating reiterated by equities researchers at Morgan Stanley in a report issued on Tuesday, March 26th, Benzinga reports.

GMAB has been the subject of several other research reports. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, March 6th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. UBS Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Hold” and an average price target of $48.50.

Genmab A/S Stock Up 1.2 %

Shares of GMAB opened at $30.27 on Tuesday. The company has a market cap of $20.00 billion, a PE ratio of 31.53, a P/E/G ratio of 1.40 and a beta of 0.98. The business has a fifty day moving average of $28.96 and a 200 day moving average of $30.89. Genmab A/S has a 52-week low of $26.32 and a 52-week high of $42.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The firm had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. As a group, research analysts anticipate that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. increased its position in shares of Genmab A/S by 21.0% during the second quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock worth $311,210,000 after purchasing an additional 1,420,915 shares in the last quarter. BlackRock Inc. increased its position in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares in the last quarter. Capital International Investors increased its position in shares of Genmab A/S by 7.7% during the first quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after purchasing an additional 283,031 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Genmab A/S by 11.1% during the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after purchasing an additional 347,437 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock worth $120,618,000 after purchasing an additional 183,578 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.